Table 1.
Patients’ characteristics and outcomes
| Characteristic | All patients N = 2564 | IPT group N = 1283 | Control group N = 1281 | P value |
|---|---|---|---|---|
| Sex: Females [Number (%)] | 1949 (76.0) | 994(77.4) | 955(74.6) | 0.083 |
| Mean age in years (±SD) | 38.6(10.3) | 39.4(±10.5) | 37.8(±10.1) | <0.001 |
| Median BMI (IQR) | 22.8(7) | 23.1(6) | 22.7(6) | <0.001 |
| Patients on ARV drugs [Number (%)] | 1913(75) | 982(76.5) | 931(72.7) | 0.025 |
| Median ARV duration in months(IQR) aN=1893 | 28.0(37) | 31.0(38) | 23(36) | <0.001 |
| Mean baseline CD4+ cells/μl (± SD), bN=2357 | 375 (±247) | 415(±261) | 330(±223) | <0.001 |
| Patients completing 6 months of IPT [N (%)] | 1263(98) | 1263(98) | - | NA |
| Patients developed TB during follow up [N (%)] | 13 (1.1) | 2 (0.2) | 11 (0.9) | 0.012 |
| Number of deaths during follow up [N (%)] | 27 (0.5) | 3(0.2) | 24(1.9) | <0.001 |
| Patients lost to follow up [N (%)] | 146(5.7) | 73(5.7) | 73(5.7) | 0.992 |
| Patients transferred out [N (%)] | 110(4.3) | 31(2.4) | 79(6.2) | <0.001 |
| Patients who withdrew consent [N (%)] | 13(0.5) | 10(0.8) | 3(0.2) | 0.052 |
| Patients who completed study | 2268(88.5) | 1166 (90.9) | 1102 (86.0) | <0.001 |
NA Not applicable
aOnly 1893 were on ARV treatment
bOnly 2357 patients had known baseline CD4 counts. Baseline here refers to the CD4 value at the time of study recruitment